Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer
| Autor: | Osamu Nagakawa, Kazuhiro Nagaike, Hideki Fuse, Takuya Akashi, Toshiya Yamagishi |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Oncology PCA3 medicine.medical_specialty animal structures Urology Proteinase Inhibitory Proteins Secretory Enzyme-Linked Immunosorbent Assay Hepatocyte Growth Factor Activator Prostate cancer Reference Values Internal medicine Biomarkers Tumor Humans Medicine In patient Hormone-Resistant Prostate Cancer Neoplasm Staging Tumor marker Membrane Glycoproteins business.industry Prostatic Neoplasms Reproducibility of Results virus diseases HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR Hyperplasia medicine.disease Endocrinology Trypsin Inhibitor Kunitz Soybean business |
| Zdroj: | The Prostate. 66:447-452 |
| ISSN: | 1097-0045 0270-4137 |
| DOI: | 10.1002/pros.20301 |
| Popis: | BACKGROUND Hepatocyte growth factor activator inhibitor type 1 (HAI-1) and type 2 (HAI-2) are Kunitz-type serine protease inhibitors for hepatocyte growth factor activator (HGFA). We attempted to clarify whether serum levels of HAI-1 and HAI-2 could be a useful marker in patients with prostate cancer. METHODS Serum levels of HAI-1 and HAI-2 were measured by enzyme-linked immunosorbent assay in 27 patients with benign prostatic hyperplasia (BPH) and 118 patients with prostate cancer. RESULTS The mean serum levels of HAI-1 in patients with prostate cancer were significantly higher than those in patients with BPH. Furthermore, the serum HAI-1 levels in patients with distant metastasis and hormone resistant prostate cancer were significantly elevated compared with those in patients with organ-confined diseases. There were no significant differences in serum HAI-2 levels among prostate cancer subgroups according to clinical stage. Significantly elevated levels of HAI-1 were detected in 38 patients with prostate cancer before any treatment. CONCLUSIONS HAI-1 may be a potential tumor marker for prostate cancer. Further studies in large groups of patients are needed to define the clinical value of HAI-1. © 2005 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text